1. Home
  2. ETON vs AFMD Comparison

ETON vs AFMD Comparison

Compare ETON & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETON
  • AFMD
  • Stock Information
  • Founded
  • ETON 2017
  • AFMD 2000
  • Country
  • ETON United States
  • AFMD Germany
  • Employees
  • ETON N/A
  • AFMD N/A
  • Industry
  • ETON Biotechnology: Pharmaceutical Preparations
  • AFMD Biotechnology: Pharmaceutical Preparations
  • Sector
  • ETON Health Care
  • AFMD Health Care
  • Exchange
  • ETON Nasdaq
  • AFMD Nasdaq
  • Market Cap
  • ETON 199.5M
  • AFMD 53.3M
  • IPO Year
  • ETON 2018
  • AFMD 2014
  • Fundamental
  • Price
  • ETON $8.82
  • AFMD $3.36
  • Analyst Decision
  • ETON Strong Buy
  • AFMD Strong Buy
  • Analyst Count
  • ETON 3
  • AFMD 5
  • Target Price
  • ETON $12.00
  • AFMD $16.25
  • AVG Volume (30 Days)
  • ETON 214.1K
  • AFMD 80.0K
  • Earning Date
  • ETON 11-11-2024
  • AFMD 11-12-2024
  • Dividend Yield
  • ETON N/A
  • AFMD N/A
  • EPS Growth
  • ETON N/A
  • AFMD N/A
  • EPS
  • ETON N/A
  • AFMD N/A
  • Revenue
  • ETON $31,381,000.00
  • AFMD $7,959,927.00
  • Revenue This Year
  • ETON $19.61
  • AFMD N/A
  • Revenue Next Year
  • ETON $35.39
  • AFMD $48.98
  • P/E Ratio
  • ETON N/A
  • AFMD N/A
  • Revenue Growth
  • ETON 8.14
  • AFMD N/A
  • 52 Week Low
  • ETON $3.03
  • AFMD $2.92
  • 52 Week High
  • ETON $8.66
  • AFMD $8.95
  • Technical
  • Relative Strength Index (RSI)
  • ETON 76.07
  • AFMD 44.84
  • Support Level
  • ETON $7.58
  • AFMD $3.28
  • Resistance Level
  • ETON $8.66
  • AFMD $3.51
  • Average True Range (ATR)
  • ETON 0.42
  • AFMD 0.17
  • MACD
  • ETON -0.07
  • AFMD 0.04
  • Stochastic Oscillator
  • ETON 91.49
  • AFMD 55.79

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Share on Social Networks: